KR20190110128A - Hsp90 억제제를 사용하여 암을 치료하는 방법 - Google Patents

Hsp90 억제제를 사용하여 암을 치료하는 방법 Download PDF

Info

Publication number
KR20190110128A
KR20190110128A KR1020197025467A KR20197025467A KR20190110128A KR 20190110128 A KR20190110128 A KR 20190110128A KR 1020197025467 A KR1020197025467 A KR 1020197025467A KR 20197025467 A KR20197025467 A KR 20197025467A KR 20190110128 A KR20190110128 A KR 20190110128A
Authority
KR
South Korea
Prior art keywords
cancer
inhibitor
bcl
hsp90 inhibitor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197025467A
Other languages
English (en)
Korean (ko)
Inventor
닐 비해리
메리렌스 에르난데스
션 란드레테
티안 수
조나단 엠. 로스버그
핸리 리첸스테인
Original Assignee
에이아이 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이아이 테라퓨틱스, 인코포레이티드 filed Critical 에이아이 테라퓨틱스, 인코포레이티드
Publication of KR20190110128A publication Critical patent/KR20190110128A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197025467A 2017-02-03 2018-02-01 Hsp90 억제제를 사용하여 암을 치료하는 방법 Ceased KR20190110128A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762454113P 2017-02-03 2017-02-03
US62/454,113 2017-02-03
US201762563991P 2017-09-27 2017-09-27
US62/563,991 2017-09-27
US201762587886P 2017-11-17 2017-11-17
US62/587,886 2017-11-17
PCT/US2018/016361 WO2018144680A1 (en) 2017-02-03 2018-02-01 Methods for treating cancer using hsp90 inhibitors

Publications (1)

Publication Number Publication Date
KR20190110128A true KR20190110128A (ko) 2019-09-27

Family

ID=63038389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025467A Ceased KR20190110128A (ko) 2017-02-03 2018-02-01 Hsp90 억제제를 사용하여 암을 치료하는 방법

Country Status (13)

Country Link
US (2) US10799508B2 (enExample)
EP (1) EP3576794A1 (enExample)
JP (1) JP2020505433A (enExample)
KR (1) KR20190110128A (enExample)
CN (1) CN110536702A (enExample)
AU (1) AU2018215336A1 (enExample)
BR (1) BR112019016024A2 (enExample)
CA (1) CA3052594A1 (enExample)
IL (1) IL268430A (enExample)
MX (1) MX2019009227A (enExample)
RU (1) RU2019127350A (enExample)
TW (1) TW201840337A (enExample)
WO (1) WO2018144680A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220036878A (ko) * 2020-09-16 2022-03-23 한국원자력의학원 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144680A1 (en) 2017-02-03 2018-08-09 Lam Therapeutics, Inc. Methods for treating cancer using hsp90 inhibitors
CN111372588A (zh) * 2017-09-27 2020-07-03 人工智能治疗公司 与hsp90抑制剂相关的治疗方法
JP2022506718A (ja) * 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｒｍｔ５阻害剤及びｂｃｌ－２阻害剤の組合せ
JP2022523073A (ja) 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
CN114126624A (zh) * 2019-06-25 2022-03-01 塔弗达治疗有限公司 Hsp90结合缀合物及其联合疗法
BR112022008683A2 (pt) 2019-11-05 2022-07-19 Abbvie Inc Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax
US20230100235A1 (en) * 2020-02-05 2023-03-30 Carna Biosciences, Inc. Anticancer agent composition
CN116615195A (zh) * 2020-09-17 2023-08-18 阿尔伯爱因斯坦医学院 使用bax激活剂的组合治疗
CA3198928A1 (en) * 2020-09-17 2022-03-24 Albert Einstein College Of Medicine Combination therapy using bax activator agent
CN118715242A (zh) * 2021-10-05 2024-09-27 得克萨斯州大学系统董事会 包含b7-h3结合多肽的组合物和方法
CN114588269B (zh) * 2022-04-06 2023-06-27 宁波大学附属人民医院 Bcl-2抑制剂和HDAC抑制剂的组合物及其用途
WO2024006292A2 (en) * 2022-06-27 2024-01-04 Foghorn Therapeutics Inc. Methods of treating cancer
CN115957328A (zh) * 2022-07-13 2023-04-14 杭州百可生物科技有限公司 一种用于治疗白血病的药物组合物以及白血病的治疗方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060253A2 (en) 2009-11-13 2011-05-19 Myrexis, Inc. Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
CN103002895A (zh) * 2010-02-12 2013-03-27 尼基制药公司 治疗血液癌症的方法
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
AU2012249322B2 (en) * 2011-04-28 2018-01-04 Sloan-Kettering Institute For Cancer Research HSP90 combination therapy
WO2018144680A1 (en) 2017-02-03 2018-08-09 Lam Therapeutics, Inc. Methods for treating cancer using hsp90 inhibitors
CN111372588A (zh) 2017-09-27 2020-07-03 人工智能治疗公司 与hsp90抑制剂相关的治疗方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220036878A (ko) * 2020-09-16 2022-03-23 한국원자력의학원 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물

Also Published As

Publication number Publication date
RU2019127350A (ru) 2021-03-03
US20210030759A1 (en) 2021-02-04
MX2019009227A (es) 2020-02-12
CN110536702A (zh) 2019-12-03
CA3052594A1 (en) 2018-08-09
TW201840337A (zh) 2018-11-16
WO2018144680A1 (en) 2018-08-09
AU2018215336A1 (en) 2019-09-12
EP3576794A1 (en) 2019-12-11
US10799508B2 (en) 2020-10-13
JP2020505433A (ja) 2020-02-20
US20180221376A1 (en) 2018-08-09
IL268430A (en) 2019-09-26
BR112019016024A2 (pt) 2020-03-31
RU2019127350A3 (enExample) 2021-05-31

Similar Documents

Publication Publication Date Title
US10799508B2 (en) Methods for treating cancer using HSP90 inhibitors
US20200253979A1 (en) Therapeutic methods relating to hsp90 inhibitors
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
CN106659716B (zh) 阿吡莫德组合物及其使用方法
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
CN107249638B (zh) 阿匹莫德用于治疗肾癌
JP2022537551A (ja) ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
EP3220908B1 (en) Compositions and methods for treating endometriosis
WO2021178449A1 (en) Compositions and methods for the treatment of pancreatic cancer
WO2013059320A1 (en) Treatment of cancers with mutant npm1 with mek inhibitors
NZ722491B2 (en) Apilimod compositions and methods for using same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190829

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210128

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230315

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230530

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230315

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I